Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
76 hedge funds and large institutions have $130M invested in Ra Pharmaceuticals, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 37 increasing their positions, 10 reducing their positions, and 11 closing their positions.
270% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 10
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
15% more funds holding
Funds holding: 66 → 76 (+10)
1% less capital invested
Capital invested by funds: $131M → $130M (-$1.79M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.9M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$14.3M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$10.4M |
| 4 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$3.22M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$4.04M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$1.06M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$850K |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$496K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$397K |
RARX Hedge Fund Activity: Q1 2018 in Review
76 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q1 2018, worth a combined $130M — down 1.4% from $131M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RARX positions and 11 closed out — a net gain of 10 holders — while 37 added to existing stakes and 10 trimmed.
The largest buyer was RA Capital Management, adding an estimated $17.9M. The largest seller was Novo Holdings A/S, cutting an estimated $4.04M.
- 76 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q1 2018, up from 66 in Q4 2017.
- Funds reported $130M of Ra Pharmaceuticals, Inc. Common Stock stock for Q1 2018, down 1.4% quarter-over-quarter.
- 21 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q1 2018 and 11 closed out, a net change of +10 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q1 2018 was RA Capital Management, an estimated $17.9M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q1 2018 was Novo Holdings A/S, an estimated $4.04M sold.
Based on aggregated 13F filings for Q1 2018.